Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs

in portfolio news

Replimune Group Inc., a biotechnology company
focused on developing next generation oncolytic immunotherapies, announced today the
completion of a $55 million Series B financing. The proceeds of the financing will
primarily be used to generate human proof of concept data for its lead product, RP1, in
multiple tumor types. The financing will also allow the Company to advance further
product candidates from its Immulytic™ platform.